Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the latest. Comments pointing out any issues are welcome. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
On April 21, 2025, Rona Therapeutics, a biotechnology company focusing on innovation in RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, its self-developed small interfering RNA (siRNA) drug targeting Angiotensinogen (AGT), has been officially approved by the National Medical Products Administration of China.RN1871 precisely inhibits the generation of the core precursor protein of the renin-angiotensin-aldosterone system (RAAS) by silencing the mRNA expression of AGT in the liver. The RAAS system is a key pathway in blood pressure regulation, and its overactivation is closely related to the progression of hypertension. Preclinical studies have shown that RN1871 can effectively reduce blood pressure over the long term, offering the potential for a better treatment option for more than 1.5 billion hypertension patients worldwide.Rona Therapeutics Founder and CEO, Ms. Yibin Shi, stated"The approval of RN1871's IND marks a significant breakthrough for Rona Therapeutics in the field of innovative therapies for chronic diseases. siRNA technology achieves long-term efficacy with extremely low dosing frequency, blocking disease progression at its source. We look forward to introducing this innovative therapy into the field of hypertension treatment, providing a safer and more convenient treatment option to improve the prevention and control of cardiovascular events and other complications."Alex M. DePaoli, MD, Chief Medical Officer and Executive Vice President of Translational Medicine at Rona Therapeutics, stated"RN1871 demonstrated significant AGT inhibitory effects and related antihypertensive efficacy in preclinical studies, with good safety. We will initiate Phase I clinical trials as soon as possible to evaluate its safety, pharmacokinetics, and early efficacy signals in humans. This progress is a concentrated manifestation of the team's ability to translate scientific insights into clinical applications."Rona Therapeutics is a global leading nucleic acid innovative drug platform company, focusing on the treatment of metabolic and neurological diseases. Rona Therapeutics is committed to developing best-in-class and first-in-class siRNA drugs with differentiation and innovation to address unmet clinical needs and improve treatment outcomes for cardiovascular diseases, obesity, and metabolic disorder-associated steatohepatitis. Additionally, Rona Therapeutics is fully unlocking the enormous potential of extrahepatic delivery technologies for neurological diseases and adipose-muscular delivery targeting various metabolic syndrome treatments.Source: Rona Therapeutics
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)